Mumbai, July 22, 2025:
Blue Jet Healthcare Limited (NSE: BLUEJET | BSE: 544009) has reported a robust set of financials for the quarter ended June 30, 2025, marking a 117.8% year-on-year (YoY) increase in revenue from operations, which stood at ₹3,548 million for Q1 FY26.

The company's performance was led by a strong uptick in its Pharmaceutical Ingredients (PI) and Active Pharmaceutical Ingredients (API) segments, with gross margins at 48.4% for the quarter. Despite a sequential decline in gross margin due to inventory adjustments and product mix shifts, Blue Jet maintained a solid EBITDA margin of 34.1%, up 693 basis points YoY.

Key Financial Highlights – Q1 FY26

Management Commentary

Mr. Shiven Arora, Managing Director, said:

“Blue Jet Healthcare clocked revenue of ₹3,548 million, a growth of 117.8% YoY with EBITDA of ₹1,210 million. This was primarily driven by the ramp-up in our PI and API product categories. Our operational strength and focus on execution continue to drive results.
Looking ahead, we remain confident in our growth strategy — supported by capacity expansions, enhanced R&D capabilities, and a robust high-value product pipeline. We are committed to delivering long-term value through innovation, efficiency, and strategic investments.”

Operational Performance Highlights:

• Revenue Growth:
  Strong growth in PI and API verticals contributed significantly to the topline, with QoQ growth of 4.2% and YoY surge of 117.8%.

• EBITDA and Profitability:
  EBITDA stood at ₹1,210 million, rising 173.3% YoY. EBITDA margin expanded by 693 bps YoY despite sequential compression due to lower overhead absorption and change in product mix.

• Net Profit:
  PAT increased by 141.3% YoY to ₹912 million, with margins improving to 25.7%.

• Sequential Decline (QoQ):
  The sequential drop in gross margin (to 48.4% from 54.7%) and PAT was attributed to lower inventory levels and reduced absorption of fixed costs during the quarter.

About Blue Jet Healthcare Limited

Blue Jet Healthcare Limited is a specialty pharmaceutical and healthcare ingredient manufacturer operating under a CDMO (Contract Development and Manufacturing Organisation) model. The company has deep expertise in contrast media intermediates and high-intensity sweeteners, catering to leading multinationals.

Blue Jet is a trusted supplier to GE Healthcare, Guerbet, and Bracco in contrast media, and also serves FMCG majors like Unilever and Colgate Palmolive India in the sweetener space.

The company has a strong innovation focus, anchored in long-term customer relationships and multi-year contracts that drive recurring revenue and sustainable profitability.

Forward-Looking Statement

This press release contains forward-looking statements subject to market risks and uncertainties. Blue Jet Healthcare undertakes no obligation to update forward-looking statements, whether as a result of new information or future events.

The Upcoming IPOs in this week and coming weeks are Sellowrap Industries, Repono, Shanti Gold International, Indiqube Spaces, GNG Electronics, Brigade Hotel Ventures, Patel Chem Specialities, TSC India, NSDL.

The Current active IPO are Monarch Surveyors & Engineering Consultants, Swastika Castal, Savy Infra.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.